CMND — Clearmind Medicine Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1892500 ·
Last close
$2.59
Market Cap
$2.64M
52W High
$15.20
52W Low
$2.10
ADV30
1,246,534
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jan 2026 | 0 | — | -3,659,915 | -3,854,583 | 11,143,419 | 9,257,766 | 2,905,011 |
| Oct 2025 | 0 | — | -1,456,258 | -687,842 | 6,083,052 | 3,923,058 | 4,890,456 |
| Jul 2025 | 0 | — | -1,407,764 | -1,313,592 | 3,969,546 | 3,495,338 | 2,903,878 |
| Apr 2025 | 0 | — | -1,306,981 | -783,928 | 5,180,456 | 4,472,520 | 2,878,986 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,554,012
Investing CF
$-611,479
Financing CF
$9,634,911
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-29.27
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-31,734,307
Inventory
—
Receivables
$437,642
ST Investments
$1,089,438
EBIT TTM
$-7,141,525
Pretax Income TTM
$-6,604,875
Interest Exp TTM
$15,776
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -5,667,177 | -3,856,983 | 6,083,052 | 4,890,456 | — | -4,734,498 |
| Oct 2024 | 0 | -5,744,925 | -5,254,678 | 7,255,414 | 4,147,862 | — | -4,858,659 |
| Oct 2023 | 0 | -6,303,434 | -8,620,837 | 5,953,288 | 4,969,816 | — | -6,301,472 |
| Oct 2022 | 0 | -6,251,431 | -6,894,868 | 826,415 | 1,932,413 | — | -3,724,494 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LIFD | LFTD PARTNERS INC. | $2.67M | $0.18 | — |
| OGEN | ORAGENICS INC | $2.67M | $0.59 | — |
| PKTX | ProtoKinetix, Inc. | $2.60M | $0.01 | — |
| VCNX | VACCINEX, INC. | $2.68M | $1.00 | — |
| PPBT | PURPLE BIOTECH LTD. | $2.70M | $2.90 | — |
News headlines (Yahoo Finance, 1h cache)
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
2026-05-26 12:25 · Yahoo
Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans?
2026-05-21 10:49 · Yahoo
Clearmind Medicine Announces 1-for-10 Reverse Share Split
2026-05-19 10:00 · Yahoo
Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND)
2026-05-18 15:17 · Yahoo
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
2026-05-18 12:42 · Yahoo
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
2026-05-15 12:35 · Yahoo
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
2026-05-12 12:41 · Yahoo
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
2026-05-11 11:55 · Yahoo
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
2026-05-05 12:50 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-04-27 13:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.